BCL-XL directly modulates RAS signalling to favour cancer cell stemness.

Abstract : In tumours, accumulation of chemoresistant cells that express high levels of anti-apoptotic proteins such as BCL-XL is thought to result from the counter selection of sensitive, low expresser clones during progression and/or initial treatment. We herein show that BCL-XL expression is selectively advantageous to cancer cell populations even in the absence of pro-apoptotic pressure. In transformed human mammary epithelial cells BCL-XL favours full activation of signalling downstream of constitutively active RAS with which it interacts in a BH4-dependent manner. Comparative proteomic analysis and functional assays indicate that this is critical for RAS-induced expression of stemness regulators and maintenance of a cancer initiating cell (CIC) phenotype. Resistant cancer cells thus arise from a positive selection driven by BCL-XL modulation of RAS-induced self-renewal, and during which apoptotic resistance is not necessarily the directly selected trait.
Type de document :
Article dans une revue
Nature Communications, Nature Publishing Group, 2017, 8 (1), pp.1123. 〈10.1038/s41467-017-01079-1〉
Liste complète des métadonnées

Littérature citée [32 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01628330
Contributeur : Elizabeth Bernardo <>
Soumis le : vendredi 3 novembre 2017 - 11:40:06
Dernière modification le : vendredi 9 février 2018 - 01:07:02

Fichier

ProofJuin.pdf
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

Citation

Sophie De Carné Trécesson, Frédérique Souazé, Agnes Basseville, Anne-Charlotte Bernard, Jessie Pécot, et al.. BCL-XL directly modulates RAS signalling to favour cancer cell stemness.. Nature Communications, Nature Publishing Group, 2017, 8 (1), pp.1123. 〈10.1038/s41467-017-01079-1〉. 〈inserm-01628330〉

Partager

Métriques

Consultations de la notice

43

Téléchargements de fichiers

11